Bès Cédric, Briant-Longuet Laurence, Cerutti Martine, Heitz Frédéric, Troadec Samuel, Pugnière Martine, Roquet Francoise, Molina Franck, Casset Florence, Bresson Damien, Péraldi-Roux Sylvie, Devauchelle Gérard, Devaux Christian, Granier Claude, Chardes Thierry
CNRS UMR 5094, Institut de Biotechnologie et Pharmacologie, Faculté de Pharmacie, 15 Avenue Charles Flahault, 34093 Montpellier Cedex 5, France.
J Biol Chem. 2003 Apr 18;278(16):14265-73. doi: 10.1074/jbc.M210694200. Epub 2003 Feb 3.
We analyzed antigen-binding residues from the variable domains of anti-CD4 antibody 13B8.2 using the Spot method of parallel peptide synthesis. Sixteen amino acids, defined as Spot critical residues (SCR), were identified on the basis of a 50% decrease in CD4 binding to alanine analogs of reactive peptides. Recombinant Fab 13B8.2 mutants were constructed with alanine residues in place of each of the 16 SCR, expressed in the baculovirus cell system, and purified. CD measurements indicated that the mutated proteins were conformationally intact, with a beta-sheet secondary structure similar to that of wild-type Fab. Compared with the CD4-binding capacity of wild-type Fab 13B8.2, 11 light (Y32-L, W35-L, Y36-L, H91-L, and Y92-L) and heavy chain (H35-H, R38-H, W52-H, R53-H, F100K-H, and W103-H) Fab single mutants showed a decrease in CD4 recognition as demonstrated by enzyme-linked immunosorbent assay, BIAcore, and flow cytometry analyses. The five remaining Fab mutants showed antigen-binding properties similar to those of wild-type Fab. Recombinant Fab mutants that showed decreased CD4 binding also lost their capacity to inhibit human immunodeficiency virus promoter activation and the antigen-presenting ability that wild-type Fab displays. Molecular modeling of the 13B8.2 antibody paratope indicated that most of these critical residues are appropriately positioned inside the putative CD4-binding pocket, whereas the five SCR that were not confirmed by mutagenesis show an unfavorable positioning. Taken together, these results indicate that most of the residues defined by the Spot method as critical matched with important residues defined by mutagenesis in the whole protein context. The identification of critical residues for CD4 binding in the paratope of anti-CD4 recombinant Fab 13B8.2 provides the opportunity for the generation of improved anti-CD4 molecules with more efficient pharmacological properties.
我们使用平行肽合成的斑点法分析了抗CD4抗体13B8.2可变区的抗原结合残基。基于与反应性肽的丙氨酸类似物结合的CD4减少50%,确定了16个氨基酸,定义为斑点关键残基(SCR)。构建了用丙氨酸残基取代16个SCR中每一个的重组Fab 13B8.2突变体,在杆状病毒细胞系统中表达并纯化。圆二色性测量表明,突变蛋白的构象完整,具有与野生型Fab相似的β-折叠二级结构。与野生型Fab 13B8.2的CD4结合能力相比,11个轻链(Y32-L、W35-L、Y36-L、H91-L和Y92-L)和重链(H35-H、R38-H、W52-H、R53-H、F100K-H和W103-H)Fab单突变体在酶联免疫吸附测定、BIAcore和流式细胞术分析中显示出CD4识别能力下降。其余五个Fab突变体显示出与野生型Fab相似的抗原结合特性。显示CD4结合减少的重组Fab突变体也失去了抑制人类免疫缺陷病毒启动子激活的能力以及野生型Fab所具有的抗原呈递能力。13B8.2抗体互补决定区的分子建模表明,这些关键残基中的大多数恰当地位于假定的CD4结合口袋内,而未通过诱变证实的五个SCR显示出不利的定位。综上所述,这些结果表明,斑点法定义为关键的大多数残基与在整个蛋白质背景下通过诱变定义的重要残基相匹配。在抗CD4重组Fab 13B8.2的互补决定区中鉴定CD4结合的关键残基为产生具有更有效药理特性的改良抗CD4分子提供了机会。